Status:
RECRUITING
Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)
Lead Sponsor:
Brainsway
Conditions:
Alcohol Use Disorder
Alcoholism
Eligibility:
All Genders
18-86 years
Phase:
NA
Brief Summary
The study will compare alcohol use in two groups of subjects. One group will be assigned to the Deep TMS treatment and the other group will be assigned to the sham treatment. This is a prospective, 6-...
Eligibility Criteria
Inclusion
- Male or female subjects, 18-86 years old.
- Subjects diagnosed with AUD and who meet criteria for moderate (4-5 out of the 12 symptoms) to severe (\> 6 out of the 12 symptoms) AUD according to the DSM-5 diagnostic criteria as determined by a licensed clinician according to the DSM-5 criteria, and verified with the Mini International Neuropsychiatric Interview (Standard MINI version 7.0.2).
- Subjects who have a history of at least 24 heavy drinking days during the 90 days prior to screening (average \>=8 HDD/month), based on TLFB).
- Treatment seeking individuals with a treatment goal of achieving abstinence or reducing heavy drinking.
- Subjects able to understand and provide signed informed consent, and able to adhere to the requirements and restrictions of this protocol.
- Satisfactory answers on safety screening questionnaire for transcranial magnetic stimulation.
Exclusion
- Subjects diagnosed with schizophrenia or chronic psychotic disorder as determined by a licensed clinician according to the DSM-5 criteria, and verified with the Mini International Neuropsychiatric Interview (Standard MINI version 7.0.2).
- Subjects with present suicidal risk as assessed by the investigator or significant suicide risk based on MADRS item 10 score of 4 or 6, or a history of attempted suicide in the last year.
- Subjects who initiated treatment with any of the following medications which are known to effect alcohol consumption, within 30 days of the Screening visit: acamprosate, baclofen, buprenorphine, disulfiram, gabapentin, naltrexone, topiramate and varenicline.
- Subjects with a significant medical illness that is not well controlled (e.g., hepatic impairment, diabetes, hypertension, heart disease, septicemia, active tuberculosis, progressive neoplasm, frequent and severe migraine headaches, etc.).
- Subjects experiencing acute alcohol withdrawal. This will be determined using the Clinical Institute Withdrawal Assessment of Alcohol - revised (CIWA-Ar) wherein subjects with a value of \>7 will not be permitted to receive TMS on that day to mitigate any potential risk of a seizure. Treatments may be rescheduled and CIWA-AR and alcohol breath tests may be reassessed, although if more than the allowed treatment sessions are missed, the subject will be withdrawn from the study.
- Subjects with a history of epilepsy or seizure (not including history of alcohol withdrawal seizure, ECT induced seizures, or childhood febrile seizures).
- Individuals with a first-degree relative family history of seizure.
- Subjects with a high risk for severe violence or suicidality as assessed during the screening interview.
- Conductive, ferromagnetic or other magnetic-sensitive metals implanted in the head (outside the mouth) or within 10 cm of the treatment coil (e.g., cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, shrapnel, surgical clips, fragments from welding or metal work).
- Subjects with cardiac pacemakers or active implantable electrodes/neurostimulators within 30 cm of the treatment coil.
- Subjects with a significant neurological disorder or insult including, but not limited to:
- Any condition likely to be associated with increased intracranial pressure
- Space occupying brain lesion
- History of cerebrovascular accident
- Transient ischemic attack within two years
- Cerebral aneurysm
- Dementia
- Mini Mental State Exam score of less than or equal to 24
- Parkinson's disease
- Huntington's chorea
- Multiple sclerosis
- Subjects suffering from significant hearing loss.
- Previous treatment with TMS within one year.
- Participation in another clinical investigation in which a device or drug has been used within 4 weeks of screening.
- If participating in psychotherapy, subject is not in stable treatment for at least 3 months prior to entry into the study or anticipates a change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the rTMS trial.
- Known or suspected pregnancy or lactation or planning to become pregnant.
- Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.
Key Trial Info
Start Date :
November 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
186 Patients enrolled
Trial Details
Trial ID
NCT07216872
Start Date
November 7 2025
End Date
December 1 2027
Last Update
November 18 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Alpha Neuron LLC
Tuscaloosa, Alabama, United States, 35401
2
Kadima Neuropsychiatry
La Jolla, California, United States, 92037
3
DTMS Center LLC
West Palm Beach, Florida, United States, 33411
4
Rosecrance River North
Chicago, Illinois, United States, 60654